⚡ FAST WATCH — updated weekly

Not yet all work peer-reviewed, but worth following:

• June 12: China launches 2000‑patient RCT of umbilical cord MSCs for ageing (301 Hospital, Beijing). Drug: Aimi maituosai (already approved for aGVHD). Primary outcomes: physical function, quality of life, safety. Multi‑centre, randomised, placebo‑controlled – the largest stem cell anti‑frailty trial to date. Prior Phase I/II (n=30) showed improved grip strength, mobility, and reduced inflammation, with no serious adverse events over 6 months. Note: The official trial announcement is in Chinese (Xinhua News Agency). The data are verified. Caveats: not a "cure for ageing"; long‑term safety unknown; China‑specific. Source (Chinese, official) →
(English summary: Xinhua News Agency reports that 301 Hospital in Beijing has initiated a 2000‑patient RCT of umbilical cord MSCs for age‑related functional decline. The drug, Aimi maituosai, is already approved in China for aGVHD.)
• June 11: Mianserin (generic antidepressant) extends mouse lifespan by restoring calcium homeostasis — Chinese study (Nature Communications, June 2026). Disruption of calcium homeostasis leads to S100A6 accumulation, triggering DNA damage, inflammation, and SASP via cGAS-STING-NF-κB pathway. Mianserin restored calcium balance and extended median lifespan by ~17.5% in naturally aged mice (started at ~65 human years) and 27.9% in progeroid mice. Caveats: Mouse study only; not tested in humans for aging. Small sample size for naturally aged cohort. Source →
• June 10: Islatravir/lenacapavir (ISL/LEN) – oral once‑weekly HIV regimen. Phase 3 ISLEND‑1 (vs Biktarvy) and ISLEND‑2 (vs standard of care) met primary endpoint at Week 48 (non‑inferiority, HIV‑1 RNA ≥50 copies/mL). Safety comparable, no new concerns. Would be first approved long‑acting oral HIV treatment if approved. Caveats: Investigational – not yet approved; Week 96 data still pending. Source →
• June 10: Sinclair announces oral "reprogramming" drug (SL‑100) for XPRIZE Healthspan — aims for 10‑year improvement in immune, cognitive, muscle function after one year. Caveats: No published data; formula confidential; chemical reprogramming requires very high concentrations in lab; another Harvard lab's similar approach failed (toxicity). Not yet in human trials. Source →
• June 10: Islatravir/lenacapavir (ISL/LEN) – oral once‑weekly HIV regimen. Phase 3 ISLEND‑1 (vs Biktarvy) and ISLEND‑2 (vs standard of care) met primary endpoint at Week 48 (non‑inferiority, HIV‑1 RNA ≥50 copies/mL). Safety comparable, no new concerns. Would be first approved long‑acting oral HIV treatment if approved. Caveats: Investigational – not yet approved; Week 96 data still pending. Source →
• June 8: Retro Biosciences (Sam Altman‑backed) Phase 1 Alzheimer's trial — oral small molecule RTR242 restores lysosomal function and enhances autophagy (cellular waste clearance). First patient dosed December 2025 in Australia. No dose‑limiting toxicities observed. Early data expected August 2026. Caveats: Phase 1 only; not yet proven to slow or reverse Alzheimer's. Source →
• June 7: Chinese mRNA combination vaccine (SIRC) targets COVID‑19, influenza, and RSV — preprint study (bioRxiv, June 2026). Single mRNA vaccine encodes antigens for three respiratory viruses. Mouse studies showed protection against lethal influenza challenge and reduced RSV lung infection. Caveats: Preclinical only (mice); not yet in human trials. Source →
• June 5: AI‑designed universal coronavirus vaccine completes Phase I trial — University of Cambridge (Journal of Infection, June 2026). Vaccine designed by machine learning to target entire Sarbecovirus family (SARS‑CoV‑2, SARS, related bat viruses). Phase I trial (n=39) showed safety and broad immune responses. Needle‑free delivery (microfluidic jet). Caveats: Immune response was modest; larger Phase II trial needed to confirm efficacy. Source →
• June 6: Isoleucine restriction extends mouse lifespan — University of Wisconsin–Madison study (Cell Metabolism, June 2026). Male and female mice fed one‑third normal isoleucine from 6 months of age had median lifespan increase from 26 to 33 months (~25‑30%), with improved metabolic health, reduced frailty, less weight gain. Mechanism: LKB1 activation boosts mitochondrial function. Human NHANES data: lower isoleucine associated with lower BMI, less inflammation. Caveats: Mouse study only; isoleucine is essential – cannot be eliminated; not a human recommendation. Source →
• June 6: Dasatinib + Quercetin (D+Q) senolytic therapy — Phase I trial in mild Alzheimer's disease reports safety data (NCT04785300). BUT: A separate University of Connecticut mouse study (PNAS, June 2026) found that D+Q caused myelin damage (nerve insulation loss) in healthy mouse brains, with younger mice affected more severely. Caveats: Mouse study results do not always translate to humans. Caution advised for self‑experimentation. Source →
• June 6: Anktiva (nogapendekin alfa inbakicept) for bladder cancer — FDA‑approved (April 2024) for BCG‑unresponsive non‑muscle invasive bladder cancer (NMIBC) with carcinoma in situ . Phase 2/3 trial (n=77): complete response rate 62% (95% CI 51‑73), 58% of responders had response ≥12 months, 40% ≥24 months . Caveats: Not first‑line; only for BCG‑unresponsive NMIBC; not for muscle‑invasive or metastatic disease. FDA label →
• June 6: Formoterol (asthma drug) shows potential for MASH reversal — MUSC study (npj Metabolic Health and Disease, March 2026). In mouse models, beta-2 adrenergic receptor agonist reversed fatty liver pathology, increased mitochondrial biogenesis. Retrospective human data (asthma patients) showed lower rates of cirrhosis and all-cause mortality. Caveats: Preclinical (mice) + observational human data. Prospective trial in diabetic kidney disease (with MASH secondary outcomes) is enrolling. Source →
• June 5: Pemvidutide (dual GLP-1/glucagon agonist) — Phase 2b trial (n=212) for MASH with F2-F3 fibrosis. 48‑week results: 54.7% liver fat reduction (1.8mg dose), 7.5% weight loss. Improved triglycerides (-23.7%), LDL cholesterol (-19.7%). Caveats: Mild-to-moderate nausea (41.2%), diarrhea (22.4%). Source →
• June 5: NewLimit raises $435M for epigenetic reprogramming therapy — mRNA-based medicine delivered via LNP reversed age in old human liver cells (preclinical). Initial focus: alcohol-related liver disease/fatty liver. Human trials planned for 2027. Backed by Founders Fund, Eli Lilly Ventures. Valuation $3.1B. Caveats: Preclinical only; exact transcription factors undisclosed. Source →
• June 5: Psilocybin in advanced Alzheimer's — case report (n=1, Frontiers in Neuroscience, May 2026). Single 5g dose led to transient multidomain functional improvement (speech, continence, memory, social interaction) in 80-year-old patient with 10‑year history. Caveats: N=1, no control group, temporary effects (duration unspecified), severe acute side effects. Not a cure; neurodegeneration remained. Source →
• June 4: GLP-1 agonists: Beyond weight loss and into the clinic for other chronic diseases. Expert analysis for 2026 predicts expanded use for heart failure, chronic kidney disease, and addiction, with large-scale trials already underway. The potential for GLP-1s as an anti-aging therapy is a leading area of investigation by major longevity research groups. Caveats: Long-term safety data for new indications is still being collected; effects vary significantly by individual. Source →
• June 3: Japan approves world‑first iPSC‑based therapies — conditional approval for Parkinson's (Amchepry, Sumitomo Pharma, n=7, 2‑year follow‑up, 4/7 improved) and severe heart failure (ReHeart, Cuorips, n=8, 2‑5 year follow‑up, improved exercise tolerance, no tumors). Caveats: Japan's conditional approval pathway; small sample sizes; long‑term safety仍需验证. Source →
• June 3: First cell‑type specific map of major depression — McGill University / Nature Genetics (2025). Analyzed >200,000 prefrontal cortex cells from 100 donors. Depression linked to altered gene regulation in two specific cell types: a stress‑responsive excitatory neuron and an immune‑regulating microglia subtype. Current antidepressants target neither. Caveats: Post‑mortem study; associative, not causal; therapeutic applications years away. Source →
• June 2: Bortz biological age clock — phenotypic algorithm (Nature Communications Biology, 2023) using 25 blood biomarkers, trained on 306k UK Biobank participants. Claims 11% better accuracy than PhenoAge for all‑cause mortality prediction. Caveats: Linear model misinterprets U‑shaped biomarkers (high cholesterol, elevated SHBG). Validated for population research, not individual clinical decisions. Source →
• June 3: Hemophilia A gene therapy (valoctocogene roxaparvovec) — 4‑year follow‑up of the Phase 3 GENEr8‑1 trial (n=134). Results: mean treated bleed rate ↓82.6%, factor VIII infusion rate ↓95.5%, 73.6% of patients had zero treated bleeds in year 4. No new safety signals. Durable benefit after single infusion. Caveats: FVIII levels may decline over time; some patients may need to resume prophylaxis. Source →
• June 3: Ziftomenib (oral menin inhibitor) for NPM1‑mutated AML — first patient dosed in Japanese Phase 2 registrational trial (April 24, 2026). Already FDA‑approved in US (Nov 2025). NPM1 mutations account for ~30% of AML cases. Source →
• June 2: Nasal spray for brain aging — Texas A&M mouse study (Journal of Extracellular Vesicles, April 2026). Two doses of extracellular vesicles (EVs) carrying microRNAs delivered intranasally to aged mice (18 months) reduced neuroinflammation, restored mitochondrial function, and improved memory tests. Caveats: Preclinical study only (mice). No human trials. Source →
• June 1: Oncolytic virus for pancreatic cancer — Phase I trial (n=3, low dose) of engineered adenovirus injected intratumorally. All 3 patients with locally advanced disease had tumour growth halted (stable disease, no shrinkage). No control group. More advanced oncolytic virus (VCN‑01) has Phase IIb data (n=96) showing improved OS and PFS in metastatic disease, with FDA‑endorsed Phase III. Caveats: Early stage, no shrinkage, locally advanced only. Source →
• June 1: SIRT6 reverses age‑related DNA "unravelling" in mouse livers — Bar‑Ilan University (Israel) study in Nature Communications. Overexpressing SIRT6 in old mice restored youthful chromatin organization, reduced inflammation, and improved metabolic function within one month. Caveats: Mouse study only; not a human therapy. Source →
• June 1: Daraxonrasib (RAS(ON) inhibitor) for metastatic pancreatic cancer — Phase 3 RASolute‑302 trial (n=500). Median OS 13.2 months vs 6.7 months chemo (HR 0.40), median PFS 7.2 vs 3.6 months (HR 0.49). First RAS‑targeted therapy with positive Phase 3 in pancreatic cancer. Caveats: Second‑line treatment only; side effects include rash. Source →

📬 Full citations added to monthly archive when peer-reviewed. Subscribe for the monthly digest.

One short email per month. No spam. Unsubscribe anytime.

Behind the archive

Dr. Andjelka Stones

Researcher & curator

🤖

MedElle

AI collaborator & research assistant

Global New World is a human‑AI collaboration. Every update is co‑constructed from peer‑reviewed science — no automation, no commercial bias.